SCIL-STROKE:皮下注射白细胞介素-1受体拮抗剂治疗缺血性卒中随机对照2期试验
SCIL-STROKE是一项单中心、双盲、随机、安慰剂对照2期试验,纳入80例急性缺血性卒中患者,皮下注射IL-1Ra 100 mg每日两次共3天。IL-1Ra显著降低血浆白细胞介素-6(P<0.001)和C反应蛋白(P<0.001),安全耐受良好,但未改善3个月改良Rankin量表结局(OR=0.67,95%CI 0.29-1.52,P=0.34)。
要点
- 皮下IL-1Ra 100 mg每日两次共3天可显著降低急性缺血性卒中患者血浆IL-6和CRP。
- IL-1Ra安全耐受良好,未发现安全性问题。
- IL-1Ra未改善3个月改良Rankin量表结局(OR=0.67,95%CI 0.29-1.52,P=0.34)。
核心结论
- IL-1Ra降低血浆炎症标志物,这些标志物已知与缺血性卒中更差临床结局相关;皮下IL-1Ra安全且耐受良好。
- 需要进一步实验研究来探究IL-1Ra的疗效及其与溶栓的可能相互作用。
研究设计与样本
- SCIL-STROKE为单中心、双盲、随机、安慰剂对照2期试验,纳入80例缺血性卒中发病5小时内患者。
- 皮下IL-1Ra 100 mg每日两次给药3天;随机化按基线美国国立卫生研究院卒中量表评分和溶栓分层。
- 在5个时间点测量血浆白细胞介素-6及其他外周炎症标志物;主要结局为至第3天log(白细胞介素-6)浓度曲线下面积的差异。
主要发现
- 共纳入80例患者,平均年龄72岁,美国国立卫生研究院卒中量表评分中位数12分,73%接受阿替普酶静脉溶栓。
- IL-1Ra显著降低血浆白细胞介素-6(P<0.001)和血浆C反应蛋白(P<0.001)。
- IL-1Ra安全耐受良好,无安全性问题。
- 分配至IL-1Ra与改良Rankin量表良好结局无关:比值比(95%置信区间)=0.67(0.29-1.52),P=0.34。
- 探索性中介分析提示IL-1Ra通过减轻炎症改善临床结局,但存在统计学显著的替代机制抵消该获益。
关键数值与推荐
- 主要结局为至第3天log(白细胞介素-6)浓度曲线下面积的差异。
- 次要结局包括IL-1Ra对3个月改良Rankin量表结局的探索性效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步实验研究来探究IL-1Ra的疗效及其与溶栓的可能相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The proinflammatory cytokine IL-1 (interleukin-1) has a deleterious role in cerebral ischemia, which is attenuated by IL-1 receptor antagonist (IL-1Ra). IL-1 induces peripheral inflammatory mediators, such as interleukin-6, which are associated with worse prognosis after ischemic stroke. We investigated whether subcutaneous IL-1Ra reduces the peripheral inflammatory response in acute ischemic stroke. METHODS: SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke) was a single-center, double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous IL-1Ra (100 mg administered twice daily for 3 days) in patients presenting within 5 hours of ischemic stroke onset. Randomization was stratified for baseline National Institutes of Health Stroke Scale score and thrombolysis. Measurement of plasma interleukin-6 and other peripheral inflammatory markers was undertaken at 5 time points. The primary outcome was difference in concentration of log(interleukin-6) as area under the curve to day 3. Secondary outcomes included exploratory effect of IL-1Ra on 3-month outcome with the modified Rankin Scale. RESULTS: We recruited 80 patients (mean age, 72 years; median National Institutes of Health Stroke Scale, 12) of whom 73% received intravenous thrombolysis with alteplase. IL-1Ra significantly reduced plasma interleukin-6 (P<0.001) and plasma C-reactive protein (P<0.001). IL-1Ra was well tolerated with no safety concerns. Allocation to IL-1Ra was not associated with a favorable outcome on modified Rankin Scale: odds ratio (95% confidence interval)=0.67 (0.29-1.52), P=0.34. Exploratory mediation analysis suggested that IL-1Ra improved clinical outcome by reducing inflammation, but there was a statistically significant, alternative mechanism countering this benefit. CONCLUSIONS: IL-1Ra reduced plasma inflammatory markers which are known to be associated with worse clinical outcome in ischemic stroke. Subcutaneous IL-1Ra is safe and well tolerated. Further experimental studies are required to investigate efficacy and possible interactions of IL-1Ra with thrombolysis. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: ISRCTN74236229.
引用
- Smith CJ, Hulme S, Vail A, et al. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial. Stroke. 2018. PMID: 29567761. doi:10.1161/STROKEAHA.118.020750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。